RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook

RxSight’s preliminary Q2 sales fell 20% year over year to about $27 million excluding collaboration revenue, with Light Adjustable Lens unit sales down 10% to 24,917. The company also sold 11 Light Delivery Devices and ended the quarter with about $209 million in cash and investments.

The Alcon collaboration boosted the outlook for 2026, with RxSight now guiding for $140 million to $160 million in revenue, including $30 million to $40 million from the deal. The company also raised its gross margin forecast to 73% to 75% while keeping operating expense guidance elevated.

Management cited competitive launches and weaker consumer sentiment as near-term headwinds that pressured procedure volumes and trialing activity. In response, RxSight plans to increase sales-force investment and continue developing next-generation products, including LAL Toric and adjustable presbyopia-correcting lenses.

RxSight NASDAQ: RXST reported preliminary second-quarter financial results and provided updates on its product pipeline following a newly announced strategic collaboration agreement with Alcon, with management pointing to both near-term commercial headwinds and longer-term opportunities in adjustable intraocular lenses.

On a conference call, President and Chief Executive Officer Dr. Ron Kurtz said RxSight has been developing proprietary hybrid intraocular lens materials intended to support next-generation light-adjustable technology across premium lens categories. He said those efforts are being pursued through both the company’s standalone product pipeline and its collaboration with Alcon.